Answers are grounded in this paper and cite their sources.
SLC7A11, a key component of the cystine/glutamate antiporter System Xc⁻, regulates redox balance and ferroptosis. Its dysregulation is linked to cancer, metabolic, neurodegenerative, immune, and kidney diseases. In tumors, SLC7A11 promotes growth and therapy resistance, while in non-cancerous tissues, it offers antioxidant protection. This review outlines the biological functions of SLC7A11, its dual disease roles, and therapeutic strategies including small molecule inhibitors, exosome delivery, and metabolic interventions. Though promising, clinical translation faces challenges in tissue specificity and metabolic compensation. Advances in precision targeting may help realize its full therapeutic potential.
No takes yet. Share an insight, caveat, or question.
Ma et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: